| Sep 3 |
Dyne Therapeutics Announces New Clinical Data from Phase 1/2 DELIVER Trial of DYNE-251 in Duchenne Muscular Dystrophy Demonstrating Unprecedented Dystrophin Expression and Functional Improvement in Multiple Cohorts
|
| Aug 29 |
Dyne Therapeutics to Present at Morgan Stanley 22nd Annual Global Healthcare Conference
|
| Aug 13 |
Dyne Therapeutics GAAP EPS of -$0.70 misses by $0.02
|
| Aug 12 |
Dyne Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights
|
| Jul 29 |
Recent Price Trend in Dyne Therapeutics (DYN) is Your Friend, Here's Why
|
| Jul 18 |
What Makes Dyne Therapeutics, Inc. (DYN) a Strong Momentum Stock: Buy Now?
|
| Jul 14 |
XPeng & QuantumScape Are Among Top 11 Mid Cap Stocks That Performed Well Last Week (July 7-July 13): Details
|
| Jul 12 |
Dyne Therapeutics (DYN) Is a Great Choice for 'Trend' Investors, Here's Why
|
| Jun 24 |
Dyne Therapeutics Presents New Preclinical Data Demonstrating the Potential of the FORCE™ Platform to Deliver Enzyme Replacement Therapy to Muscle and CNS in Pompe Disease
|
| Jun 13 |
Dyne Therapeutics Presents New Preclinical Data for its Facioscapulohumeral Muscular Dystrophy Program During the FSHD Society International Research Congress
|
